RGTLF (Argent Biopharma) Other Current Liabilities: $0.00 Mil (As of Dec. 2025)


What is Argent Biopharma Other Current Liabilities?

Argent Biopharma RGTLF Other Current Liabilities is $0.00 Mil as of Dec. 2025. The stock has 8 warning signs investors should review.

Argent Biopharma's other current liabilities for the quarter that ended in Dec. 2025 was $0.00 Mil.

Argent Biopharma's quarterly other current liabilities stayed the same from Dec. 2024 ($-0.00 Mil) to Jun. 2025 ($-0.00 Mil) but then increased from Jun. 2025 ($-0.00 Mil) to Dec. 2025 ($0.00 Mil).

Argent Biopharma's annual other current liabilities declined from Jun. 2023 ($6.16 Mil) to Jun. 2024 ($5.76 Mil) and declined from Jun. 2024 ($5.76 Mil) to Jun. 2025 ($-0.00 Mil).

Argent Biopharma Other Current Liabilities Related Terms

Argent Biopharma Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Argent Biopharma's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argent Biopharma Other Current Liabilities Chart

Argent Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.28 1.63 6.16 5.76 -0.00

Argent Biopharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.55 5.76 -0.00 -0.00 0.00

Argent Biopharma Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.00 Mil mean?
Argent Biopharma (RGTLF) has a Other Current Liabilities of $0.00 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Argent Biopharma.
Is Argent Biopharma's Other Current Liabilities too high?
Argent Biopharma's current Other Current Liabilities is $0.00 Mil.
How does Argent Biopharma's Other Current Liabilities compare to ZTS and UTHR?
Argent Biopharma's Other Current Liabilities of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Argent Biopharma. Argent Biopharma's current Other Current Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current Other Current Liabilities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current Other Current Liabilities is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argent Biopharma Business Description

Other Exchanges H5O0:GermanyRGT:Australia
Address 295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.